Evicenter
MarkdownMedical informationP&T meetings
AD109 (aroxybutynin-atomoxetine)

Obstructive sleep apnea

Also known as Oxnimbi
Manufacturer
Apnimed
Launch
Not announced
Last updated
183 sources

Clinical evidence

SynAIRgy

106 evidence topics · 17 sources

Objective
Location and study date
Registry study dates
FieldQuoted record
Study start (actual)“2023-09-16”
Primary completion (actual)“2025-03-10”
Study completion (actual)“2025-03-14”
Enrollment (actual)“646”
Registry results posting dates
FieldQuoted record
Results first submitted“2026-08-18”
Results first posted“2026-09-11”
Study design
Eligibility criteria
Inclusion and exclusion criteria in the publication

“Patients aged ≥18 years with mild-to-severe OSA who had failed or refused PAP therapy were screened for eligibility.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Participants with AHI ≥5 events/hour were initially enrolled.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“An apnea was defined by an event with ≥90% reduction in airflow for ≥10 seconds and hypopnea by ≥30% reduction in airflow for ≥10 seconds associated with a ≥4% decrease in the oxygen saturation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The eligibility criterion of enrolling participants with AHI ≥5 events/hour was subsequently changed to ≥10 to ≤45 events/hour to avoid overrepresentation of participants with very severe or very mild OSA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Other inclusion criteria were an 8-item Patient-Reported Outcomes Measurement Information System (PROMIS)–Fatigue T-score >50, representing above-average fatigue and a body mass index (BMI) of 18.5 to 40 kg/m2 in men or 18.5 to 42 kg/m2 in women.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Key exclusion criteria were clinically significant or medically uncontrolled cardiovascular disease, presence of narcolepsy, restless leg syndrome requiring medication, rapid eye movement (REM) sleep behavior disorder, bothersome symptoms of insomnia, and craniofacial malformation syndromes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Additional exclusion criteria in the design paper

“Clinically significant or medically uncontrolled cardiovascular disease, or resting heart rate >100), untreated or unstable coronary artery disease, heart failure, cerebrovascular event or revascularization within 3 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Schizophrenia, schizoaffective disorder, generalized anxiety disorder or bipolar disorder according to DSM-5 criteria” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Attempted suicide within 1 year prior to screening, or current suicidal ideation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Current bothersome symptoms of bladder outlet obstruction including difficulty initiating or maintaining urinary flow, straining, or sensation of incomplete bladder emptying” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Blood pressure >145/90 mmHg” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Narrow angle glaucoma” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Women who are pregnant or nursing” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Treatment
Study outcomes
Rationale for using Apnea-Hypopnea index as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Treatment policy estimand (intent-to-treat) and on-treatment estimand

“Primary analyses of the efficacy endpoints were performed using an intent-to-treat approach (ITT); supportive analyses were performed using the on-treatment estimand.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The ITT analysis included all randomized participants who received ≥1 dose of AD109/placebo and evaluated endpoints regardless of treatment adherence or discontinuation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“For the ITT estimand, missing data were assumed to be missing-not-at-random, and endpoints were analyzed with a pattern-mixture model using a jump-to-reference approach by means of sequential modeling with multiple imputation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The on-treatment estimand included all randomized participants who received ≥1 dose of AD109/placebo and who had ≥1 post-baseline PSG assessment on treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The on-treatment estimand focused on endpoints observed during active treatment exposure and excluded data collected after treatment discontinuation, with missing values imputed using a last observation carried forward approach.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Results
Participant disposition
Registry participant flow and reasons for study withdrawal
Milestone or reasonAD109Placebo
Started“324”“322”
Completed“269”“276”
Not completed“55”“46”
Adverse event“4”“1”
Lost to follow-up“15”“15”
Physician decision“2”“2”
Site terminated by sponsor“8”“2”
Withdrawal by subject“21”“22”
Other or not reported“5”“4”
Baseline characteristics
Baseline characteristics, intent-to-treat set, AHI with 4% desaturation hypopnea rule
CharacteristicAD109PlaceboTotal
Participants“AD109 (n = 302)”View highlighted excerpt for this quote“Placebo (n = 313)”View highlighted excerpt for this quote“Total (N = 615)”View highlighted excerpt for this quote
Age, years, median (minimum-maximum)“59 (24-83)”View highlighted excerpt for this quote“58 (25-87)”View highlighted excerpt for this quote“58 (24-87)”View highlighted excerpt for this quote
Female, n (%)“150 (49.7)”View highlighted excerpt for this quote“153 (48.9)”View highlighted excerpt for this quote“303 (49.3)”View highlighted excerpt for this quote
Black or African American, n (%)“55 (18.2)”View highlighted excerpt for this quote“62 (19.8)”View highlighted excerpt for this quote“117 (19.0)”View highlighted excerpt for this quote
White, n (%)“212 (70.2)”View highlighted excerpt for this quote“216 (69.0)”View highlighted excerpt for this quote“428 (69.6)”View highlighted excerpt for this quote
Asian, n (%)“23 (7.6)”View highlighted excerpt for this quote“22 (7.0)”View highlighted excerpt for this quote“45 (7.3)”View highlighted excerpt for this quote
Hispanic or Latino, n (%)“63 (20.9)”View highlighted excerpt for this quote“69 (22.0)”View highlighted excerpt for this quote“132 (21.5)”View highlighted excerpt for this quote
Body weight, kg, mean (SD)“93.3 (17.0)”View highlighted excerpt for this quote“93.1 (17.1)”View highlighted excerpt for this quote“93.2 (17.0)”View highlighted excerpt for this quote
BMI, kg/m2, median (minimum-maximum)“32.5 (18.5-41.9)”View highlighted excerpt for this quote“32.4 (20.1-42.0)”View highlighted excerpt for this quote“32.4 (18.5-42.0)”View highlighted excerpt for this quote
BMI 18.5-29.9 kg/m2, n (%)“107 (35.4)”View highlighted excerpt for this quote“102 (32.6)”View highlighted excerpt for this quote“209 (34.0)”View highlighted excerpt for this quote
BMI 30-34.9 kg/m2, n (%)“100 (33.1)”View highlighted excerpt for this quote“111 (35.5)”View highlighted excerpt for this quote“211 (34.3)”View highlighted excerpt for this quote
BMI 35 kg/m2 or higher, n (%)“95 (31.5)”View highlighted excerpt for this quote“100 (31.9)”View highlighted excerpt for this quote“195 (31.7)”View highlighted excerpt for this quote
AHI, events/h, median (minimum-maximum)“19.8 (5.2-101.8)”View highlighted excerpt for this quote“19.1 (5.1-70.0)”View highlighted excerpt for this quote“19.6 (5.1-101.8)”View highlighted excerpt for this quote
Mild OSA, AHI 5 to <15, n (%)“105 (34.8)”View highlighted excerpt for this quote“109 (34.8)”View highlighted excerpt for this quote“214 (34.8)”View highlighted excerpt for this quote
Moderate OSA, AHI 15 to <30, n (%)“125 (41.4)”View highlighted excerpt for this quote“134 (42.8)”View highlighted excerpt for this quote“259 (42.1)”View highlighted excerpt for this quote
Severe OSA, AHI 30 or higher, n (%)“72 (23.8)”View highlighted excerpt for this quote“70 (22.4)”View highlighted excerpt for this quote“142 (23.1)”View highlighted excerpt for this quote
ODI, events/h, median (minimum-maximum)“27.3 (6.8-96.3)”View highlighted excerpt for this quote“26.9 (4.5-79.3)”View highlighted excerpt for this quote“27.0 (4.5-96.3)”View highlighted excerpt for this quote
HB, %min/h, median (minimum-maximum)“33.7 (0.8-379.8)”View highlighted excerpt for this quote“28.8 (2.4-272.8)”View highlighted excerpt for this quote“31.1 (0.8-379.8)”View highlighted excerpt for this quote
PROMIS-Fatigue T-score, mean (SD)“59.2 (7.0)”View highlighted excerpt for this quote“58.9 (6.7)”View highlighted excerpt for this quote“59.0 (6.8)”View highlighted excerpt for this quote
PROMIS-Sleep Impairment T-score, mean (SD) [n]“58.9 (7.2) [299]”View highlighted excerpt for this quote“58.6 (7.4) [309]”View highlighted excerpt for this quote“58.7 (7.3) [608]”View highlighted excerpt for this quote
ESS score, mean (SD) [n]“10.0 (4.6) [299]”View highlighted excerpt for this quote“10.1 (4.7) [311]”View highlighted excerpt for this quote“10.0 (4.6) [610]”View highlighted excerpt for this quote
PAP intolerance, n (%)“208 (68.9)”View highlighted excerpt for this quote“203 (64.9)”View highlighted excerpt for this quote“411 (66.8)”View highlighted excerpt for this quote
PAP refusal, n (%)“94 (31.1)”View highlighted excerpt for this quote“111 (35.5)”View highlighted excerpt for this quote“205 (33.3)”View highlighted excerpt for this quote
Hypertension, n (%)“152 (50.3)”View highlighted excerpt for this quote“153 (48.9)”View highlighted excerpt for this quote“305 (49.6)”View highlighted excerpt for this quote
Diabetes, n (%)“52 (17.2)”View highlighted excerpt for this quote“51 (16.3)”View highlighted excerpt for this quote“103 (16.7)”View highlighted excerpt for this quote
Mood disturbances, n (%)“60 (19.9)”View highlighted excerpt for this quote“45 (14.4)”View highlighted excerpt for this quote“105 (17.1)”View highlighted excerpt for this quote
Insomnia, n (%)“17 (5.6)”View highlighted excerpt for this quote“15 (4.8)”View highlighted excerpt for this quote“32 (5.2)”View highlighted excerpt for this quote
Registry baseline age and mean AHI with 4% desaturation hypopnea rule, Primary Full Analysis Set
CharacteristicAD109PlaceboTotal
Age, years, mean (SD)“57.5(10.67)”“57.1(11.11)”“57.3(10.89)”
Baseline AHI4, events/hr, mean (SD)“22.13(11.819)”“21.47(10.607)”“21.79(11.214)”
Baseline oxygenation measures, all 646 randomized participants
Efficacy results
Primary and key secondary endpoints at week 26, treatment policy estimand, AHI with 4% desaturation hypopnea rule
EndpointAD109PlaceboDifference95% CIP value
Change in AHI, LS mean (95% CI), events/h (primary)“−3.3 (−5.1 to −1.5)”View highlighted excerpt for this quote“0.7 (−1.0 to 2.4)”View highlighted excerpt for this quote“−4.0”View highlighted excerpt for this quote“(−6.4 to −1.6)”View highlighted excerpt for this quote“P = .001”View highlighted excerpt for this quote
Change in ODI, LS mean (95% CI), events/h“−3.7 (−5.6 to −1.7)”View highlighted excerpt for this quote“0.9 (−1.1 to 2.8)”View highlighted excerpt for this quote“−4.5”View highlighted excerpt for this quote“(−7.3 to −1.8)”View highlighted excerpt for this quote“P = .001”View highlighted excerpt for this quote
Change in PROMIS-Fatigue T-score, LS mean (95% CI)“−7.4 (−8.3 to −6.5)”View highlighted excerpt for this quote“−6.2 (−7.1 to −5.3)”View highlighted excerpt for this quote“−1.2”View highlighted excerpt for this quote“(−2.4 to 0.0)”View highlighted excerpt for this quote“P = .059”View highlighted excerpt for this quote
Percent reduction in geometric mean HB, LS mean (95% CI)“44.7 (34.5-53.4)”View highlighted excerpt for this quote“8.5 (‒8.1 to 22.5)”View highlighted excerpt for this quote“39.6”View highlighted excerpt for this quote“(23.6-52.3)”View highlighted excerpt for this quote“P <.0001”View highlighted excerpt for this quote
Change in PROMIS-Sleep Impairment T-score, LS mean (95% CI)“−7.6 (−8.5 to −6.6)”View highlighted excerpt for this quote“−6.9 (−7.8 to −5.9)”View highlighted excerpt for this quote“−0.7”View highlighted excerpt for this quote“(−2.0 to 0.7)”View highlighted excerpt for this quote“P = .316”View highlighted excerpt for this quote
Participants with ≥50% reduction in AHI, n (%)“78 (25.8)”View highlighted excerpt for this quote“62 (19.8)”View highlighted excerpt for this quote“5.7”View highlighted excerpt for this quote“(−1.0 to 12.4)”View highlighted excerpt for this quote“P = .182”View highlighted excerpt for this quote
Primary and key secondary endpoints at week 26, on-treatment estimand, AHI with 4% desaturation hypopnea rule
EndpointAD109PlaceboDifference95% CIP value
Change in AHI, LS mean (95% CI), events/h (primary)“−6.1 (−7.8 to −4.4)”View highlighted excerpt for this quote“0.4 (−1.2 to 2.0)”View highlighted excerpt for this quote“−6.5”View highlighted excerpt for this quote“(−8.8 to −4.3)”View highlighted excerpt for this quote“P <.0001”View highlighted excerpt for this quote
Change in ODI, LS mean (95% CI), events/h“−6.5 (−8.4 to −4.6)”View highlighted excerpt for this quote“0.7 (−1.1 to 2.5)”View highlighted excerpt for this quote“−7.2”View highlighted excerpt for this quote“(−9.8 to −4.7)”View highlighted excerpt for this quote“P <.0001”View highlighted excerpt for this quote
Change in PROMIS-Fatigue T-score, LS mean (95% CI)“−7.5 (−8.4 to −6.6)”View highlighted excerpt for this quote“−6.2 (−7.0 to −5.3)”View highlighted excerpt for this quote“−1.4”View highlighted excerpt for this quote“(−2.6 to −0.1)”View highlighted excerpt for this quote“P = .030”View highlighted excerpt for this quote
Percent reduction in geometric mean HB, LS mean (95% CI)“60.5 (52.8-66.9)”View highlighted excerpt for this quote“14.7 (‒0.7 to 27.8)”View highlighted excerpt for this quote“53.6”View highlighted excerpt for this quote“(41.0-63.6)”View highlighted excerpt for this quote“P <.0001”View highlighted excerpt for this quote
Change in PROMIS-Sleep Impairment T-score, LS mean (95% CI)“−7.6 (−8.6 to −6.7)”View highlighted excerpt for this quote“−6.8 (−7.7 to −5.9)”View highlighted excerpt for this quote“−0.8”View highlighted excerpt for this quote“(−2.2 to 0.5)”View highlighted excerpt for this quote“P = .231”View highlighted excerpt for this quote
Participants with ≥50% reduction in AHI, n (%)“103 (39.6)”View highlighted excerpt for this quote“66 (22.3)”View highlighted excerpt for this quote“17.3”View highlighted excerpt for this quote“(9.6-25.0)”View highlighted excerpt for this quote“P <.0001”View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Epworth Sleepiness Scale and patient global impression endpoints

No evidence found.

Safety results
Overall safety summary, safety analysis set
EventAD109 (n = 325), n (%)Placebo (n = 319), n (%)
Any TEAE“230 (70.8)”View highlighted excerpt for this quote“149 (46.7)”View highlighted excerpt for this quote
Any treatment-related TEAE“190 (58.5)”View highlighted excerpt for this quote“75 (23.5)”View highlighted excerpt for this quote
Any severe TEAE“15 (4.6)”View highlighted excerpt for this quote“10 (3.1)”View highlighted excerpt for this quote
Any serious TEAE“5 (1.5)”View highlighted excerpt for this quote“8 (2.5)”View highlighted excerpt for this quote
Any TEAE leading to treatment discontinuation“69 (21.2)”View highlighted excerpt for this quote“10 (3.1)”View highlighted excerpt for this quote
Dry mouth“115 (35.4)”View highlighted excerpt for this quote“29 (9.1)”View highlighted excerpt for this quote
Insomnia (initial, middle, or unspecified)“67 (20.6)”View highlighted excerpt for this quote“15 (4.7)”View highlighted excerpt for this quote
Nausea“37 (11.4)”View highlighted excerpt for this quote“2 (0.6)”View highlighted excerpt for this quote
Urinary hesitation“29 (8.9)”View highlighted excerpt for this quote“1 (0.3)”View highlighted excerpt for this quote
Constipation“17 (5.2)”View highlighted excerpt for this quote“4 (1.3)”View highlighted excerpt for this quote
Somnolence“17 (5.2)”View highlighted excerpt for this quote“10 (3.1)”View highlighted excerpt for this quote
Registry adverse events at the 5% reporting threshold, safety population
EventAD109, affected/at risk (%)Placebo, affected/at risk (%)
Serious adverse events, total“5/325 (1.54%)”“8/319 (2.51%)”
Other adverse events, total“176/325 (54.15%)”“50/319 (15.67%)”
Dry mouth“115/325 (35.38%)”“29/319 (9.09%)”
Nausea“37/325 (11.38%)”“2/319 (0.63%)”
Constipation“17/325 (5.23%)”“4/319 (1.25%)”
Somnolence“17/325 (5.23%)”“10/319 (3.13%)”
Middle insomnia“38/325 (11.69%)”“10/319 (3.13%)”
Initial insomnia“30/325 (9.23%)”“4/319 (1.25%)”
Urinary hesitation“29/325 (8.92%)”“1/319 (0.31%)”
Heart rate and blood pressure, safety analysis set
Study limitations
Summary
  • Design: 26 weeks of treatment against placebo, with polysomnography at baseline and weeks 4 and 26; no active comparator. Dose reduction was not permitted, and participants could start PAP during the trial.
  • Population: adults intolerant of or refusing PAP, with a PROMIS-Fatigue T-score above 50 and a BMI cap of 40 (men) or 42 (women) kg/m2. Exclusions included clinically significant cardiovascular disease, blood pressure above 145/90 mmHg, bothersome insomnia, specified psychiatric disorders, and narrow angle glaucoma. Sites were limited to the United States and Canada, which the authors state may not represent OSA in other geographies.
  • Eligibility AHI changed during enrollment: protocol version 2.0 (July 2023) required more than 5 to 45 events/h, version 5.0 (February 2024) required 10 to 45, and the publication states participants with AHI of 5 or more were enrolled first. The 2024 congress abstract described AHI4 of 5 or more, and the 2025 abstract AHI4 above 5 with no upper limit. Enrollment ran from December 20, 2023 to March 26, 2025.
  • Severity mix: enrollment limits capped each AHI4 stratum at about 20% to 40%, and the authors state the population skewed toward mild-to-moderate disease, which can limit absolute effects; the editorial gives a median baseline AHI of 19.6.
  • Endpoint change: protocol version 4.0 (December 2023) named the proportion with at least 50% AHI reduction as the primary endpoint. Amendment 6.0 (17 April 2025) reordered the primary and key secondary endpoints “to align with recent regulatory approvals for the treatment of OSA related to obesity”. The registry version of 2025-03-18 named the proportion of participants with reduction in AHI as the primary outcome, and the next version, submitted 2025-11-18, changed the outcome measures. The amendment postdates the registry's actual primary completion date (2025-03-10). Statistical analysis plan version 2.0 (22 April 2025) added the relative change in AHI on the log scale as an exploratory analysis.
  • Estimands and missing data: the primary treatment policy analysis assumed data missing not at random (jump-to-reference multiple imputation). The supportive on-treatment estimand excluded data collected after treatment discontinuation and imputed missing values by last observation carried forward; it included 260 participants on AD109 and 296 on placebo, against 302 and 313 in the treatment policy set. The topline release reported the on-treatment relative reduction (55.6%) beside the treatment policy primary result (p=0.001).
  • Analysis-set exclusions: 22 participants (16 AD109, 6 placebo) at site 1416, terminated for Good Clinical Practice noncompliance, and 7 participants in the exploratory GLP-1 receptor agonist cohort were excluded from efficacy analyses; that cohort's analyses were not reported because of low enrollment.
  • Discontinuation: treatment discontinuation before 26 weeks was 34.3% with AD109 and 16.3% with placebo in the publication, which the authors state likely diminished the observed benefit; the prospectus reports 34.6% and 16.5% at month 6 in the main cohort. Treatment discontinuation due to adverse events was 21.2% and 3.1%; study withdrawal due to adverse events in the registry was 4 and 1 participants.
  • Hierarchical testing: under the treatment policy estimand, PROMIS-Fatigue (P = .059) did not reach significance, so formal testing ended before hypoxic burden, and the responder endpoint was not significant (P = .182).
  • Patient-reported outcomes: the authors cite a placebo response in both arms and possible expectation bias, and state insomnia was not assessed in a standardized manner although the PAP-intolerant population may have been enriched for subclinical insomnia.
  • Clinical meaningfulness: at the pre-NDA meeting the FDA gave feedback on the clinical meaningfulness of the primary endpoint results and the limitations of the PROs, and indicated additional analyses and justification may be needed. The editorial states the clinical significance of the placebo-adjusted reduction of about 4 events per hour is uncertain as a continuous measure, and that durability, long-term safety, and effects on cardiovascular events require further study.
  • Sponsor: the prospectus describes SynAIRgy as a trial the company conducted.